Pioglitazone Protected against Cardiac Hypertrophy via Inhibiting AKT/GSK3β and MAPK Signaling Pathways
作者： Wen-Ying Wei , Zhen-Guo Ma , Si-Chi Xu , Ning Zhang , Qi-Zhu Tang
DOI: 10.1155/2016/9174190
关键词:
摘要: Peroxisome proliferator activated receptor γ (PPARγ) has been closely involved in the process of cardiovascular diseases. This study was to investigate whether pioglitazone (PIO), a PPARγ agonist, could protect against pressure overload-induced cardiac hypertrophy. Mice were orally given PIO (2.5 mg/kg) from 1 week after aortic banding and continuing for 7 weeks. The morphological examination biochemical analysis used evaluate effects PIO. Neonatal rat ventricular cardiomyocytes also verify protection hypertrophy vitro. results our demonstrated that remarkably inhibited hypertrophic response induced by vivo. Besides, suppressed fibrosis treatment activation protein kinase B (AKT)/glycogen synthase kinase-3β (GSK3β) mitogen-activated (MAPK) heart. In addition, alleviated angiotensin II-induced conclusion, inhibit via attenuation AKT/GSK3β MAPK pathways.
hindawi.com
core.ac.uk 参考文章(42)
Izhak Kehat, Jeffery D. Molkentin, Extracellular signal‐regulated kinase 1/2 (ERK1/2) signaling in cardiac hypertrophy Annals of the New York Academy of Sciences. ,vol. 1188, pp. 96- 102 ,(2010) , 10.1111/J.1749-6632.2009.05088.X
Zhou-Yan Bian, He Huang, Hong Jiang, Di-Fei Shen, Ling Yan, Li-Hua Zhu, Lang Wang, Feng Cao, Chen Liu, Qi-Zhu Tang, Hongliang Li, LIM and Cysteine-Rich Domains 1 Regulates Cardiac Hypertrophy by Targeting Calcineurin/Nuclear Factor of Activated T Cells Signaling Hypertension. ,vol. 55, pp. 257- 263 ,(2010) , 10.1161/HYPERTENSIONAHA.109.135665
M. N. Ghazzi, J. E. Perez, T. K. Antonucci, J. H. Driscoll, S. M. Huang, B. W. Faja, R. W. Whitcomb, , Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group. Diabetes. ,vol. 46, pp. 433- 439 ,(1997) , 10.2337/DIAB.46.3.433
Huoyan Ji, Huimin Wang, Fupeng Zhang, Xiaohong Li, Lu Xiang, Shen Aiguo, PPARγ agonist pioglitazone inhibits microglia inflammation by blocking p38 mitogen-activated protein kinase signaling pathways Inflammation Research. ,vol. 59, pp. 921- 929 ,(2010) , 10.1007/S00011-010-0203-7
Ni-Huiping Son, Tae-Sik Park, Haruyo Yamashita, Masayoshi Yokoyama, Lesley A. Huggins, Kazue Okajima, Shunichi Homma, Matthias J. Szabolcs, Li-Shin Huang, Ira J. Goldberg, Cardiomyocyte expression of PPARγ leads to cardiac dysfunction in mice Journal of Clinical Investigation. ,vol. 117, pp. 2791- 2801 ,(2007) , 10.1172/JCI30335
Anh L. Bui, Tamara B. Horwich, Gregg C. Fonarow, Epidemiology and risk profile of heart failure Nature Reviews Cardiology. ,vol. 8, pp. 30- 41 ,(2011) , 10.1038/NRCARDIO.2010.165
Jung Ok Ban, Dong Hoon Kwak, Ju Hoon Oh, Eun-Jung Park, Min-Chul Cho, Ho Seub Song, Min Jong Song, Sang Bae Han, Dong Cheul Moon, Keon Wook Kang, Jin Tae Hong, Suppression of NF-κB and GSK-3β is involved in colon cancer cell growth inhibition by the PPAR agonist troglitazone Chemico-Biological Interactions. ,vol. 188, pp. 75- 85 ,(2010) , 10.1016/J.CBI.2010.06.001
Yibin Wang, Shuang Huang, Valerie P Sah, John Ross, Joan Heller Brown, Jiahuai Han, Kenneth R Chien, None, Cardiac Muscle Cell Hypertrophy and Apoptosis Induced by Distinct Members of the p38 Mitogen-activated Protein Kinase Family Journal of Biological Chemistry. ,vol. 273, pp. 2161- 2168 ,(1998) , 10.1074/JBC.273.4.2161
Carmine Morisco, David Zebrowski, Gianluigi Condorelli, Philip Tsichlis, Stephen F. Vatner, Junichi Sadoshima, The Akt-Glycogen Synthase Kinase 3β Pathway Regulates Transcription of Atrial Natriuretic Factor Induced by β-Adrenergic Receptor Stimulation in Cardiac Myocytes Journal of Biological Chemistry. ,vol. 275, pp. 14466- 14475 ,(2000) , 10.1074/JBC.275.19.14466
Tetsuya Shiomi, Hiroyuki Tsutsui, Shunji Hayashidani, Nobuhiro Suematsu, Masaki Ikeuchi, Jing Wen, Minako Ishibashi, Toru Kubota, Kensuke Egashira, Akira Takeshita, Pioglitazone, a Peroxisome Proliferator–Activated Receptor-γ Agonist, Attenuates Left Ventricular Remodeling and Failure After Experimental Myocardial Infarction Circulation. ,vol. 106, pp. 3126- 3132 ,(2002) , 10.1161/01.CIR.0000039346.31538.2C